The short version is that retatrutide is not just trying to suppress appetite
As Dr Sullivan commented, the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response. Dr Sullivan and colleagues concluded that these results support DMR as a promising, procedure-based strategy to maintain weight loss and potentially enable shorter-duration GLP-1 therapy. In a press release, Dr Sullivan noted, Finding a treatment that allows patients to stop [GLP-1] medications without weight regain or loss of metabolic benefit is a huge unmet need. She continued, These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance. Six-month cohort data from the REMAIN-1 trial are expected to be reported late in 2026.
These factors highlight the need for larger, prospective studies with standardized collection of both objective and patient-reported outcomes to confirm and expand our findings
Storage: Store refrigerated prior to initial use
Follow-up studies to address concerns about serious potential problems like medullary thyroid cancer have been short or not always completely reassuring
Much of what gets reported as muscle loss is not actually skeletal muscle at all